Indications that kept our investigators busy in 2011
● We tripled our phase I activity with focus on psychiatry and neurology
● 28% increase in our pain business – migraine, OA and chronic pain
● Psychiatry still core therapeutic area with depression and schizophrenia leading the way in 2011
● 70% of the total business was with CROs
